Clin2
NCT07216404Possibly a fitRecruiting

Psilocybin therapy for depression in lung cancer patients

Lung Non-Small Cell CarcinomaUnipolar Depression

Treatments studied

Part of Cancer, Lungs & breathing, Mental health clinical trials.

This trial tests whether a psychedelic-assisted therapy can help treat major depression in people with non-small cell lung cancer. If you have moderate to severe depression and are receiving cancer treatment, you may be able to join.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
10 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must have non-small cell lung cancer (NSCLC) that is confirmed by a pathology report.
  • You must have moderate to severe depression symptoms.
  • You must be at least 18 years old and speak English.
  • You must have limited past use of hallucinogens (no use in the last 5 years and less than 10 times total).
  • You cannot have certain heart conditions, insulin-dependent diabetes, or unstable brain conditions.
  • You cannot currently take certain psychiatric medications except for common antidepressants (like SSRIs, SNRIs, or low-dose bupropion).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06200155Recruiting· Phase 2
Psilocybin therapy for advanced cancer patients with anxiety or depression

This trial tests whether a drug called psilocybin, given with therapy, can help people with advanced cancer who are feeling anxious or depressed. You must have a stable cancer and be willing to travel to Houston for treatment.

Houston, Texas
NCT06801041Recruiting· Phase 2
Psilocybin therapy for anxiety or depression in cancer survivors

This trial tests if a single dose of psilocybin, given with therapy, can help cancer survivors who struggle with anxiety or depression. You would travel to MD Anderson for treatment and follow-up, and must stop certain medications beforehand.

Houston, Texas
NCT06782724Recruiting· Phase 2
Psilocybin therapy for distress in advanced illness

This trial tests whether a single dose of psilocybin (a psychedelic medicine) can help reduce depression and distress in people with advanced lung disease, ALS, multiple sclerosis, or Parkinson's. You would receive preparation, the drug, and follow-up support in a safe, supervised setting.

Prague
NCT06319378Recruiting· Phase 2
Psilocybin for cancer-related depression

This trial tests whether a single dose of psilocybin, a psychedelic medication, can safely and effectively treat major depression in people with cancer. If you have cancer and have been feeling depressed for at least a month, you may qualify.

Gothenburg, Göteborg
NCT07072728Recruiting· Phase 2
Psilocybin therapy for anxiety in cancer patients

This trial tests whether psilocybin (a psychedelic drug given with talk therapy) can help people with cancer who have adjustment disorder—a condition where a cancer diagnosis causes severe anxiety or stress. It focuses on reducing anxiety and improving emotional well-being.

Abbotsford, Victoria
NCT07281352Recruiting· Phase 1/Phase 2
Psilocybin therapy for depression

This study tests if psilocybin (a psychedelic) combined with cognitive behavioral therapy (CBT) can help people with major depression. You would receive the psilocybin in a supervised setting and have talk therapy before and after.

Los Angeles, California

Hear when a new Lung Non-Small Cell Carcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.